East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Icosapent Ethyl Capsules, 1 gram. Aurobindo Pharma’s Icosapent Ethyl Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Vascepa Capsules, manufactured by Amarin Pharmaceuticals Ireland, Limited.

Icosapent Ethyl Capsules are indicated as an:

• Adjunct to diet to reduce Triglycerides (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.